Viatris in the news
Extensive medicine portfolio supply
Tamtam found 18 recent articles about Viatris.
- Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
Viatris will announce its third-quarter 2026 financial results on November 5, 2026, with a webcast and conference call for discussion.
- Harrow Closes Acquisition of Tyrvaya, a Dry Eye Disease Treatment From Viatris Inc.
Harrow acquired worldwide rights to Tyrvaya, a dry eye disease nasal spray, from Viatris for up to $100 million, expanding its ophthalmic product portfolio.
- A third-quarter results call is set for 8:30 a.m. ET on Nov. 5, with Viatris executives hosting.
Viatris will report its third-quarter 2026 financial results on November 5, 2026, with a webcast call for investors.
- Viatris’s pipeline strategy: Moving beyond generics to find new growth
Viatris is shifting its business strategy by moving beyond traditional generics to focus on complex generics, innovative medicines, and strategic acquisitions to drive future growth.
- Should Value Investors Buy Viatris (VTRS) Stock?
Viatris (VTRS) stock is currently considered an impressive value stock due to its strong Zacks Rank, 'A' Value grade, and favorable P/B, P/S, and P/CF ratios compared to industry averages.
- Harrow Closes Acquisition of Tyrvaya from Viatris
Harrow acquired worldwide rights to Tyrvaya, a dry eye disease nasal spray, from Viatris for $30 million upfront plus potential milestones, enhancing its ocular surface portfolio.
- Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
Viatris will announce its Q3 2026 financial results on November 5, 2026, followed by a webcast and conference call.
- UBS Adjusts Price Target on Viatris to $26 From $23, Keeps Buy Rating
UBS raised Viatris's price target to $26 from $23 while keeping a 'Buy' rating.
- Viatris to report Q3 2026 earnings on Nov 5 wit...
Viatris will report its third-quarter 2026 financial results on November 5, 2026, with a webcast and conference call for discussion.
- UBS raises Viatris stock price target on cenerimod outlook
UBS increased Viatris's price target to $26.00 due to positive cenerimod outlook and strong financial performance in Q2 2026, leading to increased full-year guidance.
- Net income before discontinued operations of Viatris, Inc. – HAN:VIA
Viatris, Inc.'s net income before discontinued operations has been reported.
- Viatris Inc. stock falls Wednesday, underperforms market
Viatris Inc. stock fell 2.21% to $17.72 on Wednesday, marking its second consecutive day of losses.
- Return on invested capital % of Viatris, Inc. – HAN:VIA
This document provides the Return on Invested Capital percentage for Viatris, Inc. (HAN:VIA).
- Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
Viatris was named to Forbes' World's Best Employers list for the sixth consecutive year, based on independent global employee feedback.
- Viatris named to Forbes' World's Best Employers list for sixth year, highlighting strong workplace culture.
Viatris Inc. was named to Forbes' World's Best Employers list for the sixth consecutive year, recognizing its strong workplace culture and employee satisfaction.
- Will Japan WAKIX Approval Change Viatris (VTRS) Stock Narrative
Viatris received Japanese regulatory approval for WAKIX to treat excessive daytime sleepiness and narcolepsy, a move that aligns with its strategy to focus on higher-value specialty products.
- Is Viatris (VTRS) Cheap On Its Japan WAKIX Approval?
Viatris recently secured Japanese approval for WAKIX, contributing to strong stock performance and an undervalued assessment despite market challenges.
- Viatris sues Novo Nordisk over generic Wegovy patent dispute
Viatris has sued Novo Nordisk to challenge its patent rights for a generic version of the weight-loss drug Wegovy.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Viatris?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies